Piper Jaffray analyst David Amsellem raised his price target for Revance Therapeutics (RVNC) to $51 from $28 saying this morning’s Phase III results for RT002 are “impressive.” The stock in afternoon trading is up 38%, or $10.00, to $36.00. The company can now credibly claim that its “frown lines” treatment confers “significant benefit” for a sizable group of patients out to six months, Amsellem tells investors in an intraday research note. He thinks RT002 could offer the potential not only for less frequent procedures compared to Allergan’s (AGN) Botox but also the potential for better treatment outcomes. Allergan in afternoon trading is down $2.13 to $164.72. The analyst believes the question now for RT002 is not approvability, but rather what a differentiated label would look like. Amsellem also feels the data “should embolden” Revance to “cast a wider net in terms of the pursuit of additional indications.” He reiterates an Overweight rating on the shares.